Heart & Lung Pulmonary and Respiratory Medicine
Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation
The publisher did not provide an abstract — full text is available via the link below.